HBV vaccination in liver transplant recipients: Not an effective strategy in the prophylaxis of HBV recurrence

Basit Öğe Kaydı
dc.contributor.authorKarasu Z.
dc.contributor.authorOzacar T.
dc.contributor.authorAkarca U.
dc.contributor.authorErsoz G.
dc.contributor.authorErensoy S.
dc.contributor.authorGunsar F.
dc.contributor.authorKobat A.
dc.contributor.authorTokat Y.
dc.contributor.authorBatur Y.
dc.date.accessioned2019-10-27T00:11:05Z
dc.date.available2019-10-27T00:11:05Z
dc.date.issued2005
dc.departmentEge Üniversitesien_US
dc.description.abstractAnti-HBs immunoglobulins (HBIG) and lamivudine are main options to prevent hepatitis B virus (HBV) reinfection after liver transplantation. Although they are very effective, development of mutant viruses and high cost of treatment are main limitations for their application. Additionally there is an uncertainty for the duration of that prophylaxis regimen and its mostly applied indefinitely. Recently, post-transplant HBV vaccination is reported to be a cheaper alternative prophylaksis strategy, that enables discontinuation of HBIG. To investigate the efficacy of HBV vaccination in patients transplanted for HBV cirrhosis, we administered double course of double dose recombinant HBV vaccine (Genhavac B; containing HBV pre-S1, pre-S2, and S gene products). Vaccination has been started 1 month after HBIg discontinuation, and lamivudine (100 mg/day) was given throughout the study. The first cycle consisted of 0, 1- and 6-month schedule, and, in nonresponders, second cycle 0, 1-, 2-month schedule. Fourteen patients included into the study. Only one patient seroconverted (an anti-HBs titre of 37 IU/L) after the first cycle. No other patient responded to second cycle. HBV vaccination in the posttransplantation setting does not seems like an effective strategy in the prophylaxis of HBV recurrence. © 2005 Blackwell Publishing Ltd.en_US
dc.identifier.doi10.1111/j.1365-2893.2005.00585.xen_US
dc.identifier.endpage215en_US
dc.identifier.issn1352-0504
dc.identifier.issue2en_US
dc.identifier.pmid15720538en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage212en_US
dc.identifier.urihttps://doi.org/10.1111/j.1365-2893.2005.00585.x
dc.identifier.urihttps://hdl.handle.net/11454/22106
dc.identifier.volume12en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofJournal of Viral Hepatitisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHepatitis B virus vaccinationen_US
dc.subjectLiver transplantationen_US
dc.titleHBV vaccination in liver transplant recipients: Not an effective strategy in the prophylaxis of HBV recurrenceen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu